Modern Chinese Medicine Group Co., Ltd. has issued a profit warning, projecting a net loss of roughly RMB25.90 million for the six months ended 30 June 2026. The group posted a net profit of about RMB2.50 million in the corresponding period of 2025, marking a negative swing of approximately RMB28.40 million year on year.

Management attributes the deterioration to two main factors: 1. A sharp increase in promotion and marketing expenses linked to the company’s business expansion in Eastern China. 2. Higher research-and-development and clinical value-enhancement spending aimed at improving product quality.

The figures are based on the board’s preliminary review of unaudited management accounts and may be adjusted upon completion of the interim review. The full interim results are scheduled for release on 28 August 2026.

Shareholders and prospective investors are advised to exercise caution when dealing in the company’s securities.